BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10520053)

  • 1. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis.
    Klimek L; Dormann D; Jarman ER; Cromwell O; Riechelmann H; Reske-Kunz AB
    Clin Exp Allergy; 1999 Oct; 29(10):1326-35. PubMed ID: 10520053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine production by peripheral blood mononuclear cells following birch-pollen immunotherapy.
    Movérare R; Elfman L; Björnsson E; Stålenheim G
    Immunol Lett; 2000 Jul; 73(1):51-6. PubMed ID: 10963811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
    Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
    Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial.
    Caffarelli C; Sensi LG; Marcucci F; Cavagni G
    Allergy; 2000 Dec; 55(12):1142-7. PubMed ID: 11117271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension.
    Worm M; Rak S; Samoliński B; Antila J; Höiby AS; Kruse B; Lipiec A; Rudert M; Valovirta E
    Clin Exp Allergy; 2019 Apr; 49(4):516-525. PubMed ID: 30570787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seasonal changes in phytohemagglutinin-induced cytokine synthesis by peripheral blood lymphocytes of patients with seasonal allergic rhinitis due to Japanese cedar pollens.
    Tsuda M; Ohashi Y; Washio Y; Kakinoki Y; Nakai Y; Tanaka A; Nakai Y
    Acta Otolaryngol Suppl; 1998; 538():156-68. PubMed ID: 9879416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
    Hylander T; Latif L; Petersson-Westin U; Cardell LO
    J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate and lymphocytic response of birch-allergic patients before and after sublingual immunotherapy.
    Guida G; Boita M; Scirelli T; Bommarito L; Heffler E; Badiu I; Bellone G; Mietta S; Mistrello G; Rolla G
    Allergy Asthma Proc; 2012; 33(5):411-5. PubMed ID: 22762741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunological correlates of pre-co-seasonal sublingual immunotherapy with birch monomeric allergoid in patients with allergic rhinoconjunctivitis.
    Burastero SE; Mistrello G; Paolucci C; Breda D; Roncarolo D; Zanotta S; Falagiani P
    Int J Immunopathol Pharmacol; 2009; 22(2):343-52. PubMed ID: 19505388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios.
    Wachholz PA; Nouri-Aria KT; Wilson DR; Walker SM; Verhoef A; Till SJ; Durham SR
    Immunology; 2002 Jan; 105(1):56-62. PubMed ID: 11849315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
    Winther L; Malling HJ; Mosbech H
    Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in cytokine production in vitro during the early phase of birch-pollen immunotherapy.
    Movérare R; Elfman L; Björnsson E; Stâlenheim G
    Scand J Immunol; 2000 Aug; 52(2):200-6. PubMed ID: 10931388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term preseasonal immunotherapy: is early clinical efficacy related to the basophil response?
    Kepil Özdemir S; Sin BA; Güloğlu D; İkincioğulları A; Gençtürk Z; Mısırlıgil Z
    Int Arch Allergy Immunol; 2014; 164(3):237-45. PubMed ID: 25170594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season.
    Grindebacke H; Wing K; Andersson AC; Suri-Payer E; Rak S; Rudin A
    Clin Exp Allergy; 2004 Sep; 34(9):1364-72. PubMed ID: 15347368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cry j 1-induced synthesis of interleukin-5 and interferon-gamma by peripheral blood mononuclear cells of patients with seasonal allergic rhinitis due to Japanese cedar pollens.
    Nakai Y; Ohashi Y; Tanaka A; Kakinoki Y; Washio Y; Masamoto T; Yamada K; Nakai Y; Ohmoto Y
    Acta Otolaryngol Suppl; 1998; 538():143-51. PubMed ID: 9879414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis.
    Keen C; Johansson S; Reinholdt J; Benson M; Wennergren G
    Pediatr Allergy Immunol; 2005 May; 16(3):209-16. PubMed ID: 15853949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desensitization effect of preseasonal seven-injection allergoid immunotherapy with olive pollen on basophil activation: the efficacy of olive pollen-specific preseasonal allergoid immunotherapy on basophils.
    Gokmen NM; Ersoy R; Gulbahar O; Ardeniz O; Sin A; Unsel M; Kokuludag A
    Int Arch Allergy Immunol; 2012; 159(1):75-82. PubMed ID: 22572984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy increases CD4+CD25+ T cells in the nasal mucosa of subjects with allergic rhinitis.
    Asai K; Foley SC; Sumi Y; Yamauchi Y; Takeda N; Desrosiers M; Lavigne F; Hamid Q
    Allergol Int; 2008 Dec; 57(4):377-81. PubMed ID: 18797179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study.
    Bødtger U; Poulsen LK; Jacobi HH; Malling HJ
    Allergy; 2002 Apr; 57(4):297-305. PubMed ID: 11906359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.
    Durham SR; Ying S; Varney VA; Jacobson MR; Sudderick RM; Mackay IS; Kay AB; Hamid QA
    J Allergy Clin Immunol; 1996 Jun; 97(6):1356-65. PubMed ID: 8648033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.